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Background: Double-stranded (ds) DNA virus infections often occur concomitantly in immunocompromised
patients. We performed a systematic search of published in vitro activity for nine approved and investigational
antivirals to understand the spectrum of in vitro activity against dsDNA viruses.
Methods: A literature search was performed (PubMed and the WoS Core Collection) using keywords related to:
1) targeted approved/developmental antivirals (acyclovir, artesunate, brincidofovir, cidofovir, cyclopropavir
(filociclovir), foscarnet, ganciclovir, letermovir, and maribavir); 2) pathogenic dsDNA viruses; 3) in vitro ac-
tivity. We summarized data from 210 publications.
Results: Activity against ≤3 viruses was documented for maribavir (cytomegalovirus, Epstein-Barr virus), and
letermovir, while activity against > 3 viruses was shown for ganciclovir, cidofovir, acyclovir, foscarnet, cy-
clopropavir, artesunate, and brincidofovir. The EC50 values of brincidofovir were the lowest, ranging from 0.001
to 0.27 μM, for all viruses except papillomaviruses. The next most potent agents included cidofovir, ganciclovir,
foscarnet, and acyclovir with EC50 values between 0.1 μM and>10 μM for cytomegalovirus, herpes simplex
virus, and adenovirus.
Conclusion: Most of the identified antivirals had in vitro activity against more than one dsDNA virus.
Brincidofovir and cidofovir have broad-spectrum activity, and brincidofovir has the lowest EC50 values. These
findings could assist clinical practice and developmental research.
1. Introduction
Patients undergoing solid organ transplantation or allogeneic he-
matopoetic cell transplant (allo-HCT) are susceptible to viral infection,
including reactivation of latent double-stranded DNA (dsDNA) viruses,
due to immunosuppression required to avoid the rejection of the allo-
graft and/or to prevent graft-versus-host disease. Allo-HCT patients are
particularly at risk in the immediate post-transplant period before im-
mune reconstitution, complicating clinical management and causing
significant morbidity and mortality (Hiwarkar et al., 2018; Lion, 2014;
Park et al., 2015). An added complication of dsDNA viral reactivations
is that they can occur concomitantly in allo-HCT recipients (Ariza-
Heredia et al., 2014; Hill et al., 2017; Huang et al., 2017). The most
frequently detected dsDNA virus infections in plasma in the first 180
days after allo-HCT include cytomegalovirus (CMV) (44–65%) followed
by BK virus (BKV) (54%), human herpesvirus-6 (HHV-6) (46–61%),
adenovirus (AdV) (7–10%), and Epstein-Barr virus (EBV) (9–16%) (Hill
et al., 2017; Huang et al., 2017). Detection of multiple viruses is
common, with ≥2 viruses detected in 33–62% of allo-HCT recipients.
The overall burden of dsDNA viruses is associated with increased
mortality, indicating the unmet need for treatment options that provide
coverage against multiple viruses in this patient population (Hill et al.,
2017; Huang et al., 2017). Similarly, solid organ transplant recipients
are at an increased risk of morbidity and mortality due to dsDNA in-
fections (Beam and Razonable, 2012; Florescu et al., 2013; Leboeuf
et al., 2017; Loginov et al., 2006; Pape et al., 2016; Razonable and
Hayden, 2013). CMV is again one of the most common pathogens
(Beam and Razonable, 2012; Razonable and Hayden, 2013), while BKV
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is particularly problematic after kidney transplantation (Leboeuf et al.,
2017; Pape et al., 2016).
Although there are several approved antivirals with activity against
one or more dsDNA viruses and others in development, their spectrum
of antiviral activity and potency vary due to different mechanisms of
action. As new agents are introduced into the armamentarium, under-
standing the gaps in coverage is important to ensure optimal use and/or
novel surveillance strategies. Because most antivirals are usually ap-
proved for use against only one particular virus, labelled indications
may not adequately describe the full spectrum of coverage for a parti-
cular agent, and although data on antiviral activity in vitro are avail-
able in the scientific literature, it is scattered across multiple publica-
tions and hence is not easily accessible to clinicians managing patients
with these viral infections.
In order to ascertain the full spectrum of in vitro antiviral coverage
against the dsDNA viruses, we undertook a systematic literature review
to consolidate all available data into a single source, reporting antiviral
activities of nine available or investigational therapeutic agents against
major pathogenic human dsDNA viruses. This effort was supported by
Chimerix Inc. who assisted by supporting a professional medical writer
to undertake the literature search and assist in the drafting of the
manuscript under direction of the authors.
2. Methods
2.1. Data sources
Data on in vitro antiviral activity were retrieved from articles
published in English and obtained from searches of MEDLINE (US
National Library of Medicine, Bethesda, MD, USA) and the Web of
Science (WoS) Core Collection (Clarivate Analytics, Philadelphia, PA,
USA). All searches were performed with no limit on date of publication.
2.2. Search terms
Three searches were performed to identify publications related to:
1) the dsDNA viruses; 2) the antivirals of interest (Table 1); and 3) in
vitro activity based on half-maximal effective concentration (EC50)
data. The EC50 is the concentration at which inhibition of viral growth
is 50% of the maximum response within the specified exposure time.
The antivirals of interest include approved agents and new therapies in
development. Publications on the following nine approved/develop-
mental antivirals were identified: acyclovir, artesunate, brincidofovir,
cidofovir, cyclopropavir or filociclovir, foscarnet, ganciclovir, le-
termovir, and maribavir. The list of keywords used in each Boolean
search is detailed in Table 2. Searches were current as of October 2018.
2.3. Screening and selection
Titles and abstracts of the resulting reference list were screened;
single case reports, data from non-human dsDNA viruses, and pub-
lications not focusing on at least one of the nine antivirals of interest
were excluded.
2.4. Data extraction
For each antiviral compound, EC50 values reported in abstracts,
main text, figures, or tables of selected publications were extracted.
Data extraction was performed by one individual and independently
verified by a second individual. A hierarchical approach to data ex-
traction was employed whereby plaque reduction assay data, which is
generally considered the ‘gold standard’ assay, was categorized as the
top tier of evidence and was included if available. If this was not
available, data from DNA-based assays (including but not limited to
quantitative polymerase chain reaction [qPCR]), reporter gene assays,
or immunoassays were included. Activity against HPV is presented as
CC50 (the concentration resulting in 50% cytotoxicity) instead of an
EC50 since cytotoxicity was used as the readout for the assay. Where
values were reported in μg/ml in the original publication, these were
converted to μM using molecular weights of 225.21 for acyclovir,
255.23 for ganciclovir, 279.187 for cidofovir, and 126.005 for fos-
carnet.
For the purposes of categorizing the in vitro activity data, an EC50
value of 10 μM was selected as a suitable threshold for determining the
relative strength of the in vitro activity. For presentation purposes, data
were grouped by herpesvirus family members and non-herpesviruses.
3. Results
The systematic review identified 3429 references (after the exclusion
of 142 duplicate records). During the detailed review, 3129 references
were excluded because a) they were single case reports, b) they detailed
studies on non-human dsDNA viruses, c) they did not contain data on one
of the antivirals of interest, d) they were excluded based on our hier-
archical data extraction, or e) a combination of these factors (Fig. 1). The
final list of references comprised 210 articles, found in 85 journals with
publication dates from 1980 until 2018 (Fig. 1). In vitro activity data
against the dsDNA viruses were extracted and compiled into two separate
tables: human herpesviruses (Table 3) and other dsDNA viruses (Table 4).
Individual EC50 values were plotted on scatter plots to visualize the range
in activity for the individual antivirals (Fig. 2). Using a cut-off EC50 value
of 10 μM, the antiviral activity of each compound against the dsDNA
viruses included in the literature search was summarized and arranged
Table 1
List of antivirals with approved indications or in development.
Antiviral Status Indications Reference
Acyclovir Approved (US/EU) Treatment and prophylaxis of mucocutaneous, ocular, and systemic HSV
infections
ZOVIRAX® Prescribing Information
Ganciclovir Approved (US/EU) Treatment of CMV retinitis in immunocompromised patients.
Prevention of CMV disease in adult transplant recipients.
CYTOVENE®eIV Prescribing Information
Foscarnet Approved (US/EU) Treatment of CMV retinitis in patients with AIDS and treatment of refractory
HSV infections in immunocompromised patients
FOSCAVIR® Prescribing Information
Cidofovir Approved (US/EU) CMV retinitis VISTIDE® Prescribing Information
Brincidofovir In development In development for AdV, smallpox https://clinicaltrials.gov/ct2/show/
NCT03339401
Letermovir Approved (US/EU) Prevention of CMV reactivation in CMV seropositive adult HCT recipients PREVYMIS™ Prescribing Information
Maribavir In development In development for CMV https://clinicaltrials.gov/ct2/show/
NCT02931539
Cyclopropavir (filociclovir) In development In development for CMV https://clinicaltrials.gov/ct2/show/
NCT02454699
Artesunate In development Approved for treatment of malaria. In development for CMV. (Dondorp et al., 2005, 2010; Sharma et al.,
2014a; Wolf et al., 2011)
AdV, adenovirus; AIDS, acquired immune deficiency syndrome; CMV, cytomegalovirus; HCT, hematopoietic cell transplant; HSV, herpes simplex virus.
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based on spectrum of activity from broadest spectrum to narrowest
in the following order: brincidofovir > cidofovir > ganciclovir >
artesunate > acyclovir > cyclopropavir > maribavir > letermovir >
foscarnet (Fig. 2).
3.1. In vitro activity against the human herpesviruses
All nine antiviral compounds included in our search were reported
to have in vitro activity against one or more herpesviruses (Table 3 and
Fig. 3). Acyclovir, ganciclovir, foscarnet, cyclopropavir, cidofovir, and
brincidofovir displayed activity against> 3 herpesviruses.
In particular, acyclovir had reported EC50 values for HSV-1 ranging
from 0.11 to 18.6 μM, while values for HSV-2 ranged from 0.34 to
23 μM (Appendix A (Field et al., 2013; Leary et al., 2002; Sudo et al.,
1994)). There was a single report of an EC50 value for acyclovir of
0.0025 μM against HSV-1 using a macrophage cell line (Brand et al.,
2001). For ganciclovir, the lowest EC50 values were those reported for
CMV (range: 0.04–37.2 μM), HSV-1 (range: 0.2–0.86 μM), HSV-2
(0.016–2.5 μM), and VZV (range: 0.52–1.3 μM) (Appendix B (Andrei
et al., 2005; Andrei et al., 2000; Andrei et al., 1995; Hartline et al.,
2005b; Hobden et al., 2011; Smee et al., 1983; Zhou et al., 2009)). For
foscarnet, in vitro activity was reported for all herpesviruses, though
EC50 values ranged widely with values for CMV ranging from 27.8 μM
to 300 μM (Appendix C (Piret et al., 2016; Tatarowicz et al., 1991)). The
lowest EC50 values for cidofovir were for HHV-8 (0.05–9.2 μM), CMV
(0.26–9.5 μM), and VZV (0.5 μM) (Appendix D (Drew et al., 2006;
Hartline et al., 2005b; Kern et al., 2005; Medveczky et al., 1997;
Williams-Aziz et al., 2005)). For brincidofovir, potent activity was re-
ported against all herpesviruses, with the lowest EC50 values for VZV
(0.0004 μM) and the highest for HSV-1 (0.06 μM) (Appendix E
(Hostetler, 2009; Lanier et al., 2010; Williams-Aziz et al., 2005)). Le-
termovir had potent activity only against CMV (0.0051 μM), with EC50
values> 10 μM reported for all other herpesviruses except HHV-8, for
which no data were available (Appendix F (Marschall et al., 2012)). For
maribavir, the lowest reported EC50 values were for EBV (0.15–1.1 μM),
while the highest values were for HHV-6 (> 133 μM). Values for CMV
ranged between 0.31 and 19.4 μM (Appendix G (Chou et al., 2007;
Williams et al., 2003; Zacny et al., 1999)). Cyclopropavir had potent
activity for CMV (0.36–1.9 μM), HHV-6 (1–7.8 μM), and HHV-8
(6.5 μM) with less potent activity reported for EBV (45 μM), HSV-1
Table 2
Literature search terms.
Search Keywords
1 Cidofovir OR brincidofovir OR CMX001 OR CMX-001 OR HDP-CDV OR hexadecyloxypropyl cidofovir OR acyclovir OR ganciclovir OR foscarnet OR maribavir OR
letermovir OR 1263w94 OR AIC246 OR cyclopropavir OR filociclovir OR CMV423 OR methylenecyclopropane OR artesunate OR benzimidazole
2 Adenovirus OR herpes virus OR herpesvirus OR cytomegalovirus OR Epstein-Barr virus OR varicella zoster OR BK virus OR JC virus OR papillomavirus OR variola OR
vaccinia OR dsDNA virus
3 IC50 OR EC50 OR inhibitory concentration OR inhibition OR inhibit OR inhibitors OR susceptibility OR susceptibilities OR in vitro efficacy
4 1 AND 2 AND 3
Fig. 1. Literature search summary. Footnote: dsDNA, double-stranded DNA.
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Table 3
Antiviral activity based on EC50 values against human herpesviruses.
Virus (strain) EC50 (μM)
Acyclovir Ganciclovir Foscarnet Cidofovir Brincidofovir Letermovir Maribavir Cyclopropavir Artesunate
N=72 N=3 N=22 N=6 N=8 N=1 – N=2 –
HSV-1 0.0025–10 0.2–0.86 5.8– > 793 0.7–5.7 0.009–0.06 > 10 ND >380–420 ND
HSV-1 (KOS) 0.11–2.9 50.3–253
HSV-1 (McIntyre) 1.91
HSV-1 (McKrae) 3.2
HSV-1 (SC16) 0.15–18.6 26–> 793
N=36 N=2 N=12 N=4 N=8 N=1 – N=1 –
HSV-2 3.5–23 0.016–2.5 50.6–278 6.5–9.1 0.009–0.027 > 10 ND >380 ND
HSV-2 (G) 0.34–4.4 78.2 5.3 0.01–0.029
HSV-2 (SB5) 0.75–23 174–> 793
HSV-2 (M) 1.63–4.4
N=35 N=3 N=8 N=1 N=1 N=1 – N=1 –
VZV 28.3–130 ND >380 ND
VZV (Oka) 7 0.52–1.3 39.8–67 >10
VZV (Ellen) 3.6–16.4 0.5 0.0004
VZV (Kawaguchi) 1.18–4.1
N=18 N=8 N=2 N=8 N=3 N=1 N=1 N=1 N=2
EBV 0.3– > 10 1.17–5.0 45.3–156 1.04– > 170 0.02–0.04 >10 0.15–1.1 45 1.5–7.21
N=22 N=55 N=17 N=19 N=7 N=1 N=7 N=8 N=1
CMV (AD169) 3.8–150 0.04–6.7 27.8–300 0.6–1.1 0.001 0.0051 0.54–19.4 0.36–1.4 3.7
CMV (Coffman) 5.5 5.5–15.3 1.9 0.001 1.9
CMV (Davis) 3.4 0.6–5.9 0.5 0.001 1
CMV (Toledo) 37.2 8.2–37.2 3.8–9.5 0.03 1.3
CMV (Towne) 3.2–79 0.45–13.3 39–185 0.26–0.5 0.001 0.31 0.91
N=20 N=22 N=19 N=4 N=2 N=1 N=3 N=2 N=1
HHV-6 5.8–31 >10
HHV-6A 10–180 2.6–31.9 5.8–60 5.7–11.7 0.003 > 125–> 133 1 3.8
HHV-6B 119–185 5.2–68.6 0.7–98 1.4–1.6 0.007 > 106 6–7.8
N=6 N=6 N=5 N=5 N=1 – – N=1 –
HHV-8 31–138 0.4–23 6.5– > 449 0.05–9.2 0.02 ND ND 6.5 ND
Source references Appendix A Appendix B Appendix C Appendix D Appendix E Appendix F Appendix G Appendix H Appendix I
N=number of articles.
Bold text denotes data derived from plaque reduction assays. Non-bold text is derived from other assays, including DNA-based methods (qPCR and others), reporter
gene assays, or immunofluorescence assays. CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV, human herpesvirus; HSV, herpes simplex virus; ND, no data; VZV,
varicella zoster virus.
Table 4
Antiviral activity based on EC50 values against human non-herpesvirus dsDNA viruses.
Viral Family Virus EC50 (μM)
Acyclovir Ganciclovir Foscarnet Cidofovir Brincidofovir Letermovir Maribavir Cyclopropavir Artesunate
N=4 N=3 – N=2 N=2 N=1 – – –
Adenovirus AdV-2 > 500–> 1000 5.4 >10 ND ND ND
AdV-3 2 0.01
AdV-5 0.5–6.2 < 0.009
AdV-7 > 100 1.3 0.02
AdV-8 1 0.03
AdV-19 7.2
AdV-22 4.5
AdV-31 1.4 0.28
– – – N=1 N=1 – – – –
Papillomaviruses HPV type 11* ND ND ND 200 17 ND ND ND ND
– – – N=2 N=4 – – – N=1
Polyomaviruses BKV ND ND ND 115 0.13–0.27 ND ND ND 4.2
– – – N=1 N=4 – – –
JCV ND ND ND >0.1 0.006–0.1 ND ND ND 2.9
N=1 N=1 – N=9 – – – –
Poxviruses VACV > 144 > 392 ND 7.68–62 0.2–1.2 ND ND ND ND
– – – N=5 – – – –
VARV ND ND ND 1.37–28.45 0.05–0.21 ND ND ND ND
Source references Appendix A Appendix B Appendix C Appendix D Appendix E Appendix F Appendix G Appendix H Appendix I
N=number of articles.
Bold text denotes data derived from plaque reduction assays. Non-bold text is derived from other assays, including DNA-based methods (qPCR and others), reporter
gene assays, or immunofluorescence assays. AdV, adenovirus; BKV, BK virus; HPV, human papilloma virus; JCV, JC virus; ND, no data; VACV, vaccinia virus; VARV,
variola virus. *The HPV assay is based on cytotoxicity against HPV-transformed cell lines, therefore values reported are CC50 rather than EC50 values.
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(> 380–420 μM), HSV-2 (> 380 μM), and VZV (>380 μM) (Appendix
H (Gentry et al., 2013; Kern et al., 2005; Prichard and Whitley, 2014)).
Reported EC50 values for artesunate were relatively low, with data
available for CMV (3.7 μM), EBV (1.5–7.21 μM), and HHV-6A (3.8 μM),
but no data were available for HHV-8, HSV-1, HSV-2, and VZV
(Appendix I (Kaptein et al., 2006; Marschall et al., 2012; Milbradt et al.,
2009)).
3.2. In vitro activity against the non-herpesviruses
For non-herpesviruses, in vitro data were relatively sparse in com-
parison with the findings for herpesviruses (Table 4 and Fig. 3). In vitro
activity data were available for acyclovir against AdV (EC50 > 100
to > 1000 μM) and vaccinia virus (VACV) (EC50 > 144 μM)
(Appendix A (Kern et al., 2002; Naesens et al., 2005; Wildner et al.,
2003)). Similarly, ganciclovir had reported activity against AdV and
VACV, with the most potent activity against AdV (5.4–7.2 μM) and less
potent activity against VACV (EC50 > 392 μM) (Appendix B (Kern
et al., 2002; Taylor et al., 1988)). For cidofovir, activity was reported
against all the non-herpesviruses, with the lowest EC50 values for AdV
(0.5–6.2 μM) (Appendix D (Gordon et al., 1996; Hartline et al., 2005a)).
Similarly, brincidofovir had reported activity against all the non-her-
pesviruses, with EC50 values in the sub-μM range for all except HPV,
with the lowest values for AdV (<0.009–0.28 μM). Brincidofovir also
had potent activity against BKV (0.13–0.27 μM), JCV (0.006–0.1 μM),
VACV (0.2–1.2 μM), and variola virus (VARV) (0.05–0.21 μM)
(Appendix E (Gosert et al., 2011; Hartline et al., 2005a; Hostetler, 2009;
Jiang et al., 2010; Kern et al., 2002; Lanier et al., 2010; Olson et al.,
2014)). There was a single report of letermovir activity against AdV
(> 10 μM) (Appendix F (Marschall et al., 2012)), and reports of activity
of artesunate against JCV (2.9 μM) and BKV (4.2 μM) (Appendix I
(Sharma et al., 2014a; Sharma et al., 2014b)). There were no reports of
activity against the non-herpesviruses for foscarnet, maribavir, and
cyclopropavir.
4. Discussion
An understanding of the spectrum of antiviral activity is important
for researchers and clinicians to aid decision-making, but in vitro an-
tiviral activity data are currently scattered over hundreds of publica-
tions. Furthermore, although certain approved antivirals have activity
against multiple dsDNA viruses, approved indications are often more
narrow such that drug labels do not provide the necessary information.
To consolidate available data into a useful reference source, we un-
dertook a systematic literature search of published reports of in vitro
activity against the major pathogenic dsDNA viruses for nine develop-
mental or approved antivirals.
Our analyses highlight major differences in the breadth of antiviral
activity for different agents, and these findings are important to un-
derstand for clinical application. Few of the antivirals in our search
provide potent broad-spectrum activity against the full range of dsDNA
viruses. Using an EC50 threshold of 10 μM, brincidofovir, cidofovir,
ganciclovir, cyclopropavir, artesunate, and acyclovir had activity
against three or more dsDNA viruses, with brincidofovir having activity
against all the dsDNA virus species. At a more stringent threshold of
1 μM, brincidofovir, cidofovir, ganciclovir, and acyclovir had activity
against three or more dsDNA viruses and brincidofovir had activity
against all except HPV. Brincidofovir and cidofovir had the broadest
spectrum of antiviral activity, with brincidofovir demonstrating higher
in vitro potency (100–1000-fold greater) than cidofovir (Gosert et al.,
2011; Hartline et al., 2005a; Hostetler, 2009; Jiang et al., 2010; Kern
et al., 2002; Lanier et al., 2010; Olson et al., 2014; Williams-Aziz et al.,
2005), with EC50 values in the sub-nM to μM range (0.0004–1.2 μM).
Other antivirals either had a narrow spectrum of activity, limited data
available, or had EC50 values ranging up to>100 μM. However, it is
important to note that in vitro activity does not necessarily translate
into in vivo efficacy, as many factors play a role in determining clinical
efficacy, such as pharmacokinetics, pharmacodynamics, and toler-
ability. A high EC50 may be overcome by dosing, as is the case for
foscarnet—low in vitro activity is compensated by a high clinical dose
Fig. 2. Heat map of antivirals ordered by spectrum of
activity (EC50 < 10 μM). Antivirals were ordered according
to their spectrum of activity using an EC50 cut-off value of
10 μM. Footnote: Data for HHV-6A and HHV-6B are com-
bined in the category HHV-6. See Table 3 for separate data
for HHV-6A and HHV-6B. *Approved for treatment of CMV
retinitis in patients with AIDS and treatment of refractory
HSV infections in immunocompromised patients. Antivirals:
ACV, acyclovir; ART, artesunate; BCV, brincidofovir, CDV,
cidofovir; CPV, cyclopropavir; FOS, foscarnet; GCV, ganci-
clovir; LTV, letermovir; MBV, maribavir. Viruses: AdV, ade-
novirus; BKV, BK virus; CMV, cytomegalovirus; EBV, Epstein
Barr virus; HSV-1, herpes simplex virus-1; HSV-2, herpes
simplex virus-2; HHV-6, human herpesvirus-6; HHV-8,
human herpesvirus-8; HPV, human papilloma virus; JCV, JC
virus; VACV, vaccinia virus; VZV, varicella zoster virus;
VARV, variola virus. Note: The HPV assay is based on cyto-
toxicity against HPV-transformed cell lines, therefore values
reported are CC50 rather than EC50 values. Source references
are listed in the appendices.
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(90mg/kg IV BID), which leads to clear clinical efficacy for the treat-
ment of CMV or HSV. There may also be differences in absorption or
distribution into different body compartments such as the central ner-
vous system. Metabolism and excretion or elimination are also im-
portant characteristics to consider. Nevertheless, in vitro activity is a
good indication of the likely activity of any compound in vivo; a lack of
in vitro activity, or a high EC50 (eg,> 10 μM) value is likely to translate
into suboptimal efficacy in vivo.
Acyclovir was approved in 1982, and together with its prodrug
valacyclovir remains the mainstay of therapy for HSV and VZV infec-
tions. Prophylaxis with acyclovir is standard practice for HSV or VZV
seropositive transplant recipients, which has significantly decreased the
incidence of disease caused by these viruses (Klysik et al., 2018 [Epub
ahead of print]). Ganciclovir (and its prodrug valganciclovir) and fos-
carnet (despite its high EC50 against CMV in vitro) have been the pri-
mary agents used to treat or prevent CMV infections; because both
drugs have activity against the other human herpesviruses, they pro-
vide coverage for HSV, VZV, and HHV-6 when they are employed for
CMV prevention or preemptive therapy (Meesing and Razonable,
2018). This is not the case for some of the newer agents for treatment or
prevention of CMV (Table 1). Letermovir has been recently licensed for
prevention of CMV in allogeneic HCT recipients (Merck, 2017). It has a
novel mechanism of action that prevents CMV egress. Because its mo-
lecular target is specific to CMV, it is not active against the other dsDNA
viruses (Bowman et al., 2017; Verghese and Schleiss, 2013). Maribavir
has activity against CMV and EBV and is currently being developed to
treat CMV infection in allo-HCT patients and those with resistant/re-
fractory infections (NCT02931539), but like letermovir, does not pro-
vide coverage for all the other prevalent human herpesviruses. Cyclo-
propavir is a developmental drug under investigation for the treatment
of CMV infections. It is currently in early phase investigation as an oral
formulation (NCT02454699; NCT01433835). Brincidofovir is currently
in phase II trials for the treatment of adenovirus infection
(NCT03339401), and is also in development for the treatment of
smallpox.
The lack of coverage for HSV or VZV means that acyclovir is re-
quired to be co-administered to prevent disease due to these viruses in
patients treated with letermovir, maribavir, or cyclopropavir, although
a recent study suggests that brincidofovir may be worthy of further
study for prophylaxis and/or pre-emptive treatment of HSV and VZV in
allo-HCT recipients (Lee et al., 2018). It is also possible that HHV-6
related diseases could become more common if ganciclovir and fos-
carnet are replaced by CMV-specific agents without HHV-6 activity.
Although there are no approved treatments for HHV-6 and HHV-8,
ganciclovir, foscarnet and cidofovir, and the investigational agent
brincidofovir, have activity against these viruses (Table 3 and Fig. 3)
(Coen et al., 2014; Prichard and Whitley, 2014). Both ganciclovir and
foscarnet have been investigated as prophylaxis or preemptive therapy
Fig. 3. Scatter plot of antiviral activity vs. dsDNA viruses. All data points are plotted as open circles; some data points overlap. Data reported for CMV, HSV-1, and
HSV-2 are derived from plaque reduction assays for all reported antivirals, as were data for VZV using acyclovir, cidofovir, brincidofovir, letermovir, and foscarnet.
Data for EBV and HHV-8 were derived from methods that include reporter gene assays and DNA-based methods (including qPCR), as were data for HHV-6 using
brincidofovir and for HSV-2 using ganciclovir. AdV, adenovirus; BKV, BK virus; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HHV, human herpesvirus; HSV,
herpes simplex virus; JCV, JC virus; qPCR, quantitative polymerase chain reaction; VACV, vaccinia virus; VARV, variola virus; VZV, varicella zoster virus. Footnote:
Data for HHV-6A and HHV-6B are combined in the category HHV-6. See Table 3 for separate data for HHV-6A and HHV-6B.
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for HHV-6 infection in high-risk allo-HCT recipients; however, these
studies have not shown an improvement in outcomes (Ishiyama et al.,
2011, 2012; Ogata et al., 2008, 2013, 2018). The authors of this study
speculated that this may be due to failure of these drugs to penetrate the
cerebrospinal fluid to therapeutically relevant levels. On the other
hand, the lipid conjugate brincidofovir may penetrate the cerebrospinal
fluid more efficiently (Tippin et al., 2016) which potentially comple-
ments its very low EC50 in vitro (Table 3, Fig. 3).
There are no approved treatments for diseases caused by AdV, BKV,
or JCV in the US or EU. Most of these infections are generally managed
clinically with cidofovir, despite known kidney and hematologic toxi-
city (Gilead, 2010). Artesunate is an intriguing agent, which has been
licensed to treat malaria, but has also been investigated to treat CMV
(with mixed results) and been reported to have activity against HHV-6,
BKV, and JCV (Sharma et al., 2014a, 2014b). There are no licensed
antiviral options for therapeutic treatment of HPV, though topical ci-
dofovir has been used for patients with severe HPV infections (Stier
et al., 2013).
A major limitation of our review is that there is no consensus
methodology for assessing antiviral activity across different dsDNA
viruses. Consequently, EC50 values can vary greatly between publica-
tions. Although the plaque reduction assay is considered the ‘gold
standard’ for assessing antiviral activity, it is not applicable for all
viruses and it can be employed with a variety of modifications that may
affect the results obtained. For example, the characteristics of the cell
line such as the passage number or growth characteristics can influence
the findings, as can the passage number of the virus used in the assay,
and/or whether a clinical isolate or a laboratory strain was used. Other
factors such as the method of preparation or isolation of the virus can
also influence assay results (Tille, 2013). There are also differences in
how individual laboratories score and characterize plaques based on
plaque size. Despite these differences, the plaque reduction assay re-
mains the most accepted assay for assessing in vitro antiviral activity,
and our data extraction strategy was designed to identify and report
these data where available. Where plaque reduction assay data were
not available, data from other assay techniques such as reporter gene
assays, DNA-based techniques such as qPCR, or immunofluorescence
assays were reported. In these assays, factors such as multiplicity of
infection (infectious virus units/cell) or growth phase of the cells could
have an impact on the assay results. Nevertheless, by including data
from these assays where plaque reduction assay data are not available,
our systematic review presents a comprehensive overview of the
available literature. An additional limitation is that the compounds
used in the publications included in our literature search came from a
variety of sources and may have different levels of purity and activity.
The absence of standardized methodology for assessing antiviral
activity has been addressed by two recent articles that describe the
development of a robust in vitro testing platform using an automated
384-well format. The readout was based either on qPCR or cytopathic
effect; these methods were used to assess the activity of a panel of
antivirals against polyomaviruses, herpesviruses, orthopoxviruses, and
adenovirus (Hartline et al., 2018; Keith et al., 2018). Their investigation
demonstrated consistent and robust results that were in accordance
with data from previously published work, including the activity data
described in our systematic review. It should be pointed out that data
presented in this review is generated by several investigators using
different assay methods, including data generated from plaque reduc-
tion assays. This raises the possibility of improvements in the capacity
to assess antiviral activity of existing agents in the future or the iden-
tification of new agents with potential antiviral activity.
Despite the limitations inherent in comparing data across many
publications with a range of antiviral assays, this systematic review
represents the first comprehensive resource gathering the most current
information on the overall in vitro antiviral activity of available and
developmental antivirals against major pathogenic dsDNA viruses. We
found that the spectrum of antiviral activity ranged from broadest to
narrowest, based on a cut-off value of 10 μM, as follows: brincido-
fovir > cidofovir > ganciclovir > artesunate > acyclovir >
cyclopropavir > maribavir > letermovir > foscarnet (Fig. 3). While
in vitro values may not necessarily translate into clinical efficacy, we
believe that this review is a useful resource for clinicians and re-
searchers seeking a consolidated description of in vitro antiviral activity
against the dsDNA viruses, particularly those managing im-
munocompromised patients who are at the greatest risk of disease from
these viruses.
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